HHC-Associated Psychosis: Distinct Clinical Features in Irish Inpatient Cohort

Distinct Clinical Profile of HHC-Associated Psychosis

Hexahydrocannabinol (HHC)-associated psychosis is characterized by higher rates of affective symptoms and formal thought disorder compared to cannabis-associated psychosis, according to a retrospective cohort study at University Hospital Galway, Ireland. The study, published on October 19, 2026 (OpenAlex W7222986776), reviewed all adult acute mental health admissions between May 2023 and July 2025 with recent HHC or cannabis use and a diagnosis of psychosis. Among 33 patients (79% male), all HHC-only cases occurred during a first episode of psychosis. Affective symptoms (such as mood disturbances) were observed in 89% of HHC-only cases, compared to 54% in cannabis-only and 27% in combined HHC+cannabis groups. Formal thought disorder was also more prevalent in HHC-exposed patients (80%) than in those with cannabis-only presentations (38%).

Mechanisms and Context: HHC’s Emergence and Detection Challenges

HHC is a semi-synthetic cannabinoid, structurally related to delta-9-tetrahydrocannabinol (THC), but with distinct pharmacological properties that remain poorly characterized in humans. The study’s findings suggest that HHC may have a different neuropsychiatric risk profile than traditional cannabis, potentially due to its unique interaction with cannabinoid receptors or other neurochemical systems. Notably, all HHC-related psychosis cases were first-episode, raising questions about whether HHC could trigger psychosis in previously unaffected individuals. Standard urine toxicology screens detected THC metabolites but may miss HHC, complicating diagnosis and clinical management. This detection gap represents a concrete failure mode not widely addressed in current psychiatric protocols, underscoring the need for updated toxicology panels as novel cannabinoids proliferate.

Policy and Research Implications: Screening and Protocols

The emergence of HHC-associated psychosis with distinct clinical features has direct implications for psychiatric care and public health policy. The study’s authors recommend implementing novel cannabinoid screening in psychiatric settings to facilitate earlier identification and tailored management. For regulators, these findings highlight the importance of monitoring the mental health impact of new cannabinoids entering the market, especially as HHC is often sold online or in unregulated retail settings in Europe and elsewhere. The data also suggest that clinical trials and observational studies should stratify by specific cannabinoid exposure, rather than grouping all cannabis-related cases together. This approach could yield more precise risk assessments and inform evidence-based guidelines for clinicians.

Risks, Limitations, and Unknowns

HHC-associated psychosis carries potential risks including more pronounced affective disturbances and thought disorder, but the evidence remains preliminary. The Galway study’s small sample size (n=33), single-site design, and exploratory statistical approach limit the generalizability of its findings. Multiple testing was not corrected, and confounding factors such as polysubstance use or pre-existing psychiatric vulnerability were not fully controlled. The long-term outcomes of HHC-associated psychosis, including relapse rates and functional recovery, are unknown. Additionally, the lack of routine HHC detection in toxicology screens may lead to underreporting or misattribution of cases, impeding accurate surveillance and intervention.

Looking Forward: Surveillance, Research, and Regulatory Action

As novel cannabinoids like HHC become more accessible, psychiatric services and policymakers face new challenges in detection, diagnosis, and risk mitigation. The Galway study provides an early signal that HHC may not be clinically interchangeable with cannabis, warranting targeted research and surveillance. Future studies should prioritize larger, multi-center cohorts, standardized cannabinoid testing, and longitudinal follow-up to clarify causality and long-term effects. Regulators may need to consider proactive measures, such as requiring HHC-specific toxicology in psychiatric admissions and evaluating the public health impact of emerging cannabinoids before widespread commercialization. For now, clinicians should remain vigilant for atypical psychotic presentations and advocate for updated screening protocols in mental health settings.

By Dr. Eleanor Walsh, MB BCh BAO, MSc (Neuropsychiatry). Reviewed by Dr. Michael O’Shea, FRCPsych, on 2026-10-20. Research based on primary clinical data from University Hospital Galway and published study W7222986776.